Compare SPOT & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPOT | SNY |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | Sweden | France |
| Employees | N/A | 74846 |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.3B | 107.3B |
| IPO Year | 2015 | N/A |
| Metric | SPOT | SNY |
|---|---|---|
| Price | $473.04 | $46.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 27 | 5 |
| Target Price | ★ $723.70 | $58.00 |
| AVG Volume (30 Days) | 1.9M | ★ 3.7M |
| Earning Date | 04-28-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.43% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.65 | $3.01 |
| Revenue Next Year | $13.81 | $5.80 |
| P/E Ratio | $38.70 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $405.00 | $43.32 |
| 52 Week High | $784.77 | $55.77 |
| Indicator | SPOT | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 41.43 | 58.78 |
| Support Level | $453.68 | $45.20 |
| Resistance Level | $512.42 | $48.97 |
| Average True Range (ATR) | 17.91 | 0.76 |
| MACD | -5.70 | 0.37 |
| Stochastic Oscillator | 10.13 | 77.94 |
Spotify is the leading global music streaming service provider, with over 750 million monthly active users and 290 million paying subscribers, with the latter constituting the firm's premium segment. Most of the firm's revenue and nearly all its gross profit come from the subscribers, who pay a monthly fee to access a music library that consists of most of the most popular songs ever recorded, including all from the major record labels. The firm also offers access to audiobooks and integrates podcasts within its standard music app. Podcast content is not exclusive and is typically free to access on other platforms. Ad-supported users can access a similar music catalog but cannot customize a similar on-demand experience.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.